- Previous Close
0.0000 - Open
-- - Bid --
- Ask --
- Day's Range
-- - 52 Week Range
0.0260 - 0.1450 - Volume
-- - Avg. Volume
0 - Market Cap (intraday)
-- - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, hepatology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company was founded in 1867 and is based in Dublin, Ireland.
www.mallinckrodt.com2,673
Full Time Employees
--
Fiscal Year Ends
Sector
Recent News: MCKPF
View MorePerformance Overview: MCKPF
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MCKPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MCKPF
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
-0.01
Enterprise Value/EBITDA
0.02
Financial Highlights
Profitability and Income Statement
Profit Margin
-157.56%
Return on Assets (ttm)
0.38%
Return on Equity (ttm)
-791.29%
Revenue (ttm)
1.89B
Net Income Avi to Common (ttm)
-2.97B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
389.8M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
230.15M